91063-19-3

Basic information

• Product Name: 3-CHLORO-6-BENZYLOXYPYRIDAZINE
• Synonyms: 3-CHLORO-6-BENZYLOXYPYRIDAZINE
• CAS NO: 91063-19-3
• Molecular Formula: C₁₁H₉ClN₂O
• Molecular Weight: 220.65496
• Mol File: 91063-19-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-CHLORO-6-BENZYLOXYPYRIDAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-6-BENZYLOXYPYRIDAZINE(91063-19-3)
• EPA Substance Registry System: 3-CHLORO-6-BENZYLOXYPYRIDAZINE(91063-19-3)

Safety Data

• Hazardous Substances Data: 91063-19-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Chloro-6-benzyloxypyridazine is utilized as a key intermediate in the synthesis of pharmaceuticals. Its unique structural features allow for the development of heterocyclic compounds with diverse biological activities, contributing to the creation of new drugs with potential therapeutic benefits.
Used in Agrochemical Production:
In the agrochemical industry, 3-chloro-6-benzyloxypyridazine serves as a building block for the production of various compounds with applications in agriculture. Its ability to form heterocyclic compounds with different biological properties makes it a valuable asset in the development of new agrochemicals aimed at enhancing crop protection and productivity.
Used in Organic Synthesis:
3-Chloro-6-benzyloxypyridazine is also employed as a versatile building block in organic synthesis. Its structural features enable the production of a wide range of compounds with medicinal and agricultural applications, further expanding its utility in the fields of chemistry and material science.
Ongoing Research and Development:
Due to its potential applications and structural features, 3-chloro-6-benzyloxypyridazine is the subject of ongoing research and development in the fields of chemistry, pharmaceuticals, and agrochemicals. Scientists and researchers are continually exploring new ways to harness its properties and expand its uses in creating innovative solutions for various industries.

Upstream product

• 141-30-0 3,6-dichlorpyridazine 
• 20194-18-7 sodium phenyl-methanolate 
• 100-51-6 benzyl alcohol 

Downstream Products

• 3605-12-7 3-benzyloxy-1,6H-pyridazin-6-one 
• 454182-03-7 3-benzyloxy-6-mercapto-pyridazine 

Relevant articles and documents

2-HETEROARYL-PYRROLO [3,4-C]PYRROLE DERIVATIVES, AND USE THEREOF AS SCD INHIBITORS

The invention relates to compounds of the formula (I), where the groups R1, M, A, B, D, L, and R have the specified meanings, and to the physiologically compatible salts thereof. The compounds are suitable, for example, for treating metabolic syndrome, in

(HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS

The present invention relates to (hetero)aryl compounds of general formula (I) wherein the groups and radicals A, B, Q, W, X, Y, Z, R1, R2, R4a, R4b, R5a, R5b, have the meanings given in cl

Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors

This invention relates to novel sulfonyl pyridazinone compounds useful as aldose reductase inhibitors in the treatment or prevention of certain complications arising from diabetes mellitus, pharmaceutical compositions comprising the sulfonyl pyridazinone, pharmaceutical compositions comprising a combination of the sulfonyl pyridazinone together with a second pharmaceutical agent, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds in combination with a second pharmaceutical agent and compounds useful as intermediates for preparing the sulfonyl pyridazinone compounds of this invention.

Therapies for tissue damage resulting from ischemia

This invention relates to therapeutic methods for treatment or prevention of tissue damage resulting from ischemia in mammals.

Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors

Compounds of the formula (I): a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug, wherein R1, R2, X and Y are as defined in the claims are aldose reductase inhibitors useful in the treatment or p

Pyridazinone aldose reductase inhibitors

The present invention relates to novel pyridazinone compounds, pharmaceutical compositions comprising those compounds and to methods of using such compounds and compositions to inhibit aldose reductase, lower sorbitol levels and, thus, lower fructose levels, and/or treat or prevent diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals. This invention also relates to methods of affording cardioprotection to subjects not suffering from diabetes. This invention also relates to pharmaceutical compositions and kits comprising a combination of an aldose reductase inhibitor (ARI) of this invention and a sorbitol dehydrogenase inhibitor and to methods of using such compositions or kits to treat or prevent the above diabetic complications in mammals. This invention also relates to other combinations with the ARIs of this invention, including combinations with adendsine agonists; NHE-1 inhibitors; glycogen phosphorylase inhibitors; selective serotonin reuptake inhibitors; GABA agonists; antihypertensive agents; 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; phosphodiesterase-5 inhibitors; and to glucose lowering agents.